| Purpose | Board Meetings Date | Announcement Date |
|---|---|---|
| Board Meeting | 30 Jan 2026 | 12 Jan 2026 |
| Ajanta Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/01/2026 inter alia to consider and approve Unaudited Financial Results for quarter ended 31st December 2025. Pls find enclosed results for quarter ended 31st December 2025. (As Per BSE Announcement Dated on: 30/01/2026) | ||
| Board Meeting | 3 Nov 2025 | 8 Oct 2025 |
| Ajanta Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 03/11/2025 inter alia to consider and approve Unaudited consolidated and standalone financial results for the second quarter and half year ended 30th September 2025 PFA Board Meeting Outcome (As Per BSE Announcement Dated on: 03.11.2025) | ||
| Board Meeting | 28 Jul 2025 | 16 Jul 2025 |
| Ajanta Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 28/07/2025 inter alia to consider and approve Unaudited financial results for the quarter ended 30.06.2025. PFA Unaudited Financial Results for quarter ended 30.06.2025. (As Per BSE Announcement Dated on: 28/07/2025) | ||
| Board Meeting | 30 Apr 2025 | 22 Apr 2025 |
| Ajanta Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/04/2025 inter alia to consider and approve Audited Financial results for the quarter and year ended 31st March 2025 PFA Audited Results Outcome of the Board Meeting PFA Intimation w.r.t re-appointment of Mr. Madhusudan Agrawal. (As Per BSE Announcement Dated on 30.04.2025) | ||
Profit after tax for the nine months ended December 2025 rose 14% year on year to ₹789 crore, compared with ₹695 crore in the year ago period
EBITDA margin for the quarter came in at 27.8%, slightly lower than 28% recorded in the year ago period.
The company plans to launch the product after securing all necessary regulatory approvals, which are expected to be received between late 2026 and early 2027.
Ajanta Pharma reported a strong EBITDA margin of 25% in the quarter.
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2026, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016, BSE Enlistment Number (RA): 5016
ARN NO : 47791 (AMFI Registered Mutual Fund & Specialized Investment Fund Distributor), PFRDA Reg. No. PoP 20092018
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
